Cancer Pain Clinical Trial
Official title:
Adequacy of Pain Treatment in Radiotherapy: an Observational, Prospective, Multicenter Study (ARISE)
NCT number | NCT03550599 |
Other study ID # | ARISE |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 1, 2018 |
Est. completion date | June 1, 2019 |
Aim of the study is to evaluate adequacy of pain treatment in oncologic patients, accessing to Radiotherapy Unit
Status | Recruiting |
Enrollment | 2000 |
Est. completion date | June 1, 2019 |
Est. primary completion date | March 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - patients accessing to Radiotherapy Unit for radiation treatment (both palliative or with radical intent) with diagnosis of primitive or metastatic cancer; Exclusion Criteria: - Concomitant diseases that can affect reliability of collected data |
Country | Name | City | State |
---|---|---|---|
Italy | Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi Hospital | Bologna | BO |
Lead Sponsor | Collaborator |
---|---|
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of adequacy of pain treatment | For all patients, Visual Analogue Scale (VAS) and information about type of analgesic drugs (no drugs; non-opioid drugs; weak opioids; strong opioids) will be recorded and analysed | 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03375515 -
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
|
Phase 3 | |
Recruiting |
NCT03431922 -
Endovascular Denervation in Patients With Cancer Pain
|
N/A | |
Not yet recruiting |
NCT05265052 -
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
|
Phase 2 | |
Withdrawn |
NCT05325164 -
Methadone for 'Adenocarcinopathic' Pain Treatment
|
Phase 3 | |
Completed |
NCT02664987 -
Analgesic Treatment for Cancer Pain in South East Asia
|
N/A | |
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Active, not recruiting |
NCT04095234 -
Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT)
|
Phase 2 | |
Recruiting |
NCT05800834 -
Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds
|
Phase 2 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT02609828 -
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
|
Phase 3 | |
Completed |
NCT03331055 -
PENS or TENS for Pain in Pancreatic Cancer
|
N/A | |
Recruiting |
NCT05506878 -
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
|
N/A | |
Completed |
NCT00766831 -
An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain
|
Phase 4 | |
Recruiting |
NCT05051735 -
PARASTOP - Paracetamol With Strong Opioids
|
Phase 3 | |
Not yet recruiting |
NCT05348174 -
Randomized Controlled Trial of Virtual Reality Assisted Guided Imagery (VRAGI) for Pain in Advanced Cancer Patients.
|
N/A | |
Completed |
NCT05209906 -
An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain
|
||
Completed |
NCT03031938 -
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
|
Phase 3 | |
Not yet recruiting |
NCT05594459 -
Early Treatment With Invasive Technique in Cancer Pain Management
|
N/A | |
Withdrawn |
NCT04666623 -
Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
|
Phase 2 | |
Not yet recruiting |
NCT05049811 -
Effects of Mobile Medicine on Cancer Patients
|
N/A |